Shield Therapeutics (LSE:STX) Stock Based Compensation : £0.68 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Stock Based Compensation?

Shield Therapeutics's Stock Based Compensation for the six months ended in Dec. 2024 was £0.22 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was £0.68 Mil.

Shield Therapeutics Stock Based Compensation Historical Data

The historical data trend for Shield Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Stock Based Compensation Chart

Shield Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

0.78

1.01

0.75

0.69

0.68

Shield Therapeutics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Stock Based Compensation	Get a 7-Day Free Trial															-0.05	0.14	0.55	0.46	0.22

Shield Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.68 Mil.

Shield Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.